Addition of CMO, Medical Director Chris Polage, MD, and enhancements in clinical operations position Company for success in the clinical development of ALX1 in bronchiectasis
MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer. Dr. Bruinenberg brings over 30 years of experience as a clinical development executive in respiratory medicine and orphan diseases. This appointment and the recent addition of microbiologist and clinical diagnostics expert Chris Polage, MD, as Medical Director, significantly bolster the company's clinical development expertise in pulmonary infectious diseases and medical microbiology.
"Paul's development experience will guide Vast Therapeutics as we successfully transition to a clinical-stage organization," said Nate Stasko, Chief Executive Officer at Vast Therapeutics. "He's been here before. His early-stage clinical experience in cystic fibrosis and non-cystic fibrosis bronchiectasis patient populations is a perfect match for our drug candidates that we believe will reshape the respiratory infectious disease landscape."
"It is an amazing opportunity to join a company with an accepted IND for a novel treatment modality that shows promising efficacy against chronic infections caused by Pseudomonas aeruginosa and non-tuberculosis mycobacteria," commented Paul Bruinenberg, Chief Medical Officer at Vast Therapeutics. "The high unmet medical need in this therapeutic area is significant. I am excited to advance our nebulized therapy to maximize clinical outcomes for these patients without concerns of renal toxicity and emergence of antibiotic resistance."
Vast plans to initiate its Phase 1 clinical development program in Q2 2024 and one or more proof-of-concept studies in subjects with bronchiectasis in 2025.
Paul Bruinenberg, MD, MBA – Chief Medical Officer
Dr. Bruinenberg has over 30 years' experience in the pharmaceutical and biotechnology industry. He brings a wealth of respiratory infectious disease experience researching rare diseases like cystic fibrosis (CF), non-CF bronchiectasis (NCFB), tuberculosis (TB) and non-tuberculosis mycobacteria (NTM). His career includes development of several inhaled therapies including the approval of Pulmozyme® as the first mucolytic for CF as well as the early development of inhaled liposomal ciprofloxacin for the treatment of chronic Pseudomonas aeruginosa infections.
Most recently, Dr. Bruinenberg served as the Senior Medical Officer of the TB Alliance leading clinical development against mycobacterial infections. Previously, he held medical leadership roles at Eagle Pharmaceuticals, Aradigm Corporation, Astellas and Roche, having a key role in the development and approval of 12 new drugs (Pulmozyme®, Pretonamid®, Globocef®, Rocephin®, Quinodis® Bosentan®, Xolair®, CellCept®, Zenapax®, Belrapzo®, Bendeka®, and Ryanodex®). Dr. Bruinenberg is a graduate of the medical school of the University of the Stellenbosch, South Africa and obtained two MBAs from the University of Nijenrode in the Netherlands and Rochester University in the USA.
Chris Polage, MD – Medical Director
Dr. Polage is a physician-scientist and board-certified medical microbiologist with NIH clinical research training and over 15 years of experience leading top academic clinical laboratories. His award-winning research and publications have been cited more than 2500 times in the medical and scientific literature and changed medical practice regarding the diagnosis and treatment of C. difficile, an urgent antimicrobial resistance threat. Before coming to Vast, he was Medical Director of the Duke University Clinical Microbiology Laboratory where he oversaw specialized testing for a broad array of patient populations including CF and NCFB patients. Dr. Polage is a diagnostics expert for the NIAID/NIH Antimicrobial Resistance Leadership Group and an adjunct Associate Professor of Pathology at Duke University. He received his Doctor of Medicine from the University of New Mexico with residency and fellowship training at the University of Colorado and University of Utah/ARUP Laboratories, including two years of medical microbiology with a special focus on mycobacterial testing.
About Vast Therapeutics
Vast is a life science company focused on breaking the debilitating cycle of infection and chronic inflammation in respiratory diseases. This cycle affects patients across the entire spectrum of human life, ranging from children with rare orphan diseases like Cystic Fibrosis to adults with highly prevalent diseases like chronic obstructive pulmonary disease (COPD). We believe our product candidates may provide an effective treatment for patients infected with Pseudomonas aeruginosa, NTM, and other drug-resistant microbes.
Contact:
Nathan Stasko
Chief Executive Officer
Vast Therapeutics, Inc.
[email protected]
SOURCE Vast Therapeutics, Inc.
Share this article